BioAtla Inc (BCAB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.30+7.44%
Close 2026-09-03 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BCAB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
BCAB — legal / regulatory event — Notice
Dated 2026-08-28
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) had determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 555…
Why it matters: Updates on asset sales show how BioAtla is using its resources and growing.
Supportive ifManagement announces asset sales that bring in cash or lower debt.
Worry ifNo news on asset sales means ongoing financial problems.
Why it matters: Completing the merger is crucial for BioAtla's future structure and operations. It may stabilize the company.
Supportive ifThe merger transaction is completed by the end of 2026 as planned.
Worry ifThe merger is delayed beyond the end of 2026.
Why it matters: Finishing the workforce reduction may lower costs and improve efficiency. This could help stabilize the company.
Supportive ifAn announcement that the job cuts are done and savings are in place.
Worry ifDelays or issues in completing the workforce reduction.
Why it matters: The merger's success is important for BioAtla's future and how it works.
Supportive ifThe merger is now official and the new structure is in place.
Worry ifDelays or issues arise that prevent the merger from being effective.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$349 on $10,000 · ±3.5% | How much price usually moves either way. |
| Bad day | $1,406 loss on $10,000 · 14.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,802 loss on $10,000 · 98.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Asset sales could provide cash and improve the company's financial health. Investors will watch for clarity on this strategy.
Supportive ifA press release confirming a sale of an asset or a new partnership.
Worry ifNo updates or failed sales show that there are still financial problems.
Why it matters: Updates on job cuts may show progress in managing costs and restructuring.
Supportive ifBioAtla announces job cuts that save at least $2 million each year.
Worry ifThere will be no updates on job cuts or restructuring in the next quarter.
Why it matters: A workforce reduction could lower costs and improve efficiency. This is key for restructuring efforts.
Supportive ifAn announcement with the number of jobs lost and cost savings expected.
Worry ifNo job cuts announced, showing ongoing business issues.
Why it matters: Fixing the delisting notice is important for BioAtla's market presence and trust.
Worry ifThe company solves the Nasdaq delisting notice and stays compliant.
Less concerning ifThe company does not fix the delisting notice, which leads to delisting.
Why it matters: Updates on job cuts will show how BioAtla is saving money during changes.
Worry ifManagement says they cut jobs. This will save money.
Less concerning ifJob cuts are not done or cause problems in operations.
Why it matters: Completing the merger is key for BioAtla's future. It shows management's ability to execute plans.
Supportive ifThe merger is done and will be effective by April 6, 2026.
Worry ifThe merger is delayed or not completed by the end of 2026.
Why it matters: Any asset sales could provide cash flow and improve the company's financial health.
Supportive ifManagement announces an asset sale that brings in over $5 million in cash.
Worry ifThere will be no news on asset sales in the next quarter.
Why it matters: Fixing the delisting notice is key for BioAtla's market presence and trust from investors.
Supportive ifA press release stating that the Nasdaq delisting notice has been resolved by July 2026.
Worry ifNo resolution announcement by the next earnings date on August 6, 2026.
Why it matters: Dealing with the delisting notice is important for staying in the market and keeping investor trust.
Supportive ifThe company made a public statement. It says they follow Nasdaq listing rules.
Worry ifFailure to address the delisting notice by the next earnings report on August 6, 2026.
Why it matters: How BioAtla reacts to the Nasdaq notice will affect its market position.
Worry ifBioAtla meets Nasdaq rules and avoids being taken off the list.
Less concerning ifBioAtla fails to address the notice, leading to potential delisting.
Why it matters: News about selling assets or partnerships could affect BioAtla's finances and plans.
Watch forManagement shares news of a big asset sale or partnership.
Also watch forNo updates on strategic options show a lack of direction.
Why it matters: Completing the workforce reduction is key to restructuring. It can lower costs and improve efficiency.
Supportive ifAn announcement says workforce cuts will be done by July 2026.
Worry ifNo completion announcement by the next earnings date on August 6, 2026.